Resistance Mechanisms and Molecular Testing in ALK Inhibitor–Treated NSCLC

Panelists explain that resistance to targeted therapy often arises through secondary mutations or bypass signaling pathways. Recognizing these patterns is critical for sequencing subsequent therapies effectively. Advanced molecular testing, including plasma-based assays, allows clinicians to identify emerging resistance early and adjust treatment accordingly.

The conversation also explores new research mapping the molecular evolution of ALK-positive disease under treatment pressure. These insights are enabling the development of next-generation inhibitors designed to overcome resistance mutations.

Overall, panelists emphasize that incorporating molecular monitoring at progression helps ensure continued precision in therapy selection and sustains long-term disease control.